Tech Company Financing Transactions

Proniras Funding Round

Proniras closed a $4.7 million Series B venture capital round on 2/1/2024. Investors included Accelerator Life Science Partners, Arch Venture Partners and private investors.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

2815 Eastlake Ave. E 300
Seattle, WA 98102
USA

Phone

(206) 957-7300

Website

www.proniras.com

Email Address

[email protected]

Overview

Proniras is a specialty pharmaceutical company focused on the development of drugs for orphan neurological diseases with high unmet medical need. The Company's lead program is tezampanel, a novel AMPA/kainate receptor antagonist which antagonizes glutamate signaling in the central nervous system.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Thong Le

        

Chief Operating Officer

David Schubert

        

Chief Scientific Officer

Christopher Toombs

        

VP - Finance

Lindsay Rayle

        

Browse more venture capital transactions:

Prev: 2/1/2024: Watershed venture capital transaction
Next: 2/1/2024: Perelel venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to record funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary